Our Orchard

The Potential to Transform Lives Through Gene Therapy Development

Jesus Garcia-Segovia, Vice President, Global Head Translational Medicine & Sr. Adviser Clinical Development
March 29, 2021

In my career as a neurologist, I have encountered a wide range of rare, devastating neurodegenerative and neurometabolic diseases, many of which have no approved treatment options. Despite attempts to develop disease-modifying therapies for these diseases, complex pathogenic mechanisms coupled with difficulties for small molecules and biologics to cross the blood-brain barrier have hampered clinical development.

Five years ago, after over 20 years of working with neurodegenerative and neurometabolic diseases, I was drawn to Orchard Therapeutics, which at the time was a new biotech company founded on the goal of bringing one-time, potentially curative gene therapies to patients with these severe conditions. Even in the company’s early stages, I knew the gene therapy approach that Orchard employs was set to play a key role in addressing key pathogenic mechanisms of multiple inherited diseases. I was particularly excited by Orchard’s innovative approach of using a patients’ own (autologous) hematopoietic stem cells (HSCs) to cross the blood-brain barrier, distribute in the brain, engraft as microglial-like cells, and express the missing or faulty gene—a process which has the potential to persistently correct the underlying cause of disease in a single treatment.

Shortly after Orchard was established, I joined the team as head of clinical development for neurometabolic disorders and have recently become global head of translational medicine across our disease portfolio. Managing the development of the neurometabolic and neurological assets in our pipeline from translational research through clinical development and registration for the last five years has served as a strong foundation and natural transition into my new role working with cross-functional teams to maximize the probability of success of first in human studies for indications like frontotemporal dementia with progranulin mutations (GRN-FTD) and amyotrophic lateral sclerosis (ALS).

Today, Orchard has made significant progress across its neurodegenerative and neurometabolic portfolio, capped by the recent European Commission (EC) approval for its first HSC gene therapy for a neurometabolic disease, representing an extraordinary leap forward for the field and the promise of a new era in the treatment of severe genetic diseases. Bringing our first gene therapy to market in Europe is a remarkable achievement of our clinical development team, our partners at San Raffaele Telethon Institute for Gene Therapy and the rare disease community.

Our work doesn’t stop here, however, and we will continue working to harness the power of HSC gene therapy to bring potentially curative treatments to patients living with severe inherited conditions. We believe there is great potential for the application of HSC gene therapy in a growing range of neurometabolic and neurodegenerative disorders of high unmet need. Our understanding of the biology of disease, the mechanism by which HSC gene therapy exerts its effect and the clinical validation in rare diseases has helped pave the way for our development programs for less-rare neurometabolic and immunological conditions, including GRN-FTD, ALS and NOD2-Crohn’s disease.

I believe that Orchard’s HSC gene therapy approach has the potential to transform lives, and we are extremely excited about the possibilities for patients with the devastating genetic diseases we aim to treat.

You may also like…

Our Orchard

The Importance of Orchard’s Core Values for Our Bold Vision

As we pass the one-year mark of the beginning of the COVID-19 pandemic, the collective shift to at-home work, and my transition to the role of chief executive officer at Orchard, I...

Read More Featured
Our Orchard

Celebrating Orchard’s 5 Year Anniversary

As we celebrate Orchard’s five-year anniversary this September, I flash back to when I sat together at a coffee shop with my good friend and colleague, Nicolas Koebel, to start sha...

Our Orchard

My engagement and leadership at Orchard and why it’s important

I’ve always felt strongly about the power in collaboration and connections to drive growth. When I joined Orchard as VP, Global Head of Pharmacovigilance in January 2020, I was ini...

Title of the wysi

The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie policy.

Please read our privacy policy and cookie policy for more information on the cookies we use and how to delete or block the use of cookies.